Business
AJCN endorses Sirco
AJCN endorses Sirco.
About this update from Provexis Plc
[{"type":"text","content":"\n Provexis PLC\n16 May 2006\n\n\n PROVEXIS PLC\n\n ('Provexis' or the 'Company')\n\n SircoTM science to be published in leading scientific journal\n\nProvexis, the nutraceutical company that develops scientifically-proven\nfunctional and medical foods, announces a major international scientific\nendorsement for its lead product SircoTM. Two scientific papers, which detail\nthe clinical efficacy of SircoTM, are to be published by the American Journal of\nClinical Nutrition (AJCN). The AJCN is internationally recognised as the\nhighest-ranked peer-reviewed journal in the nutrition field.\n\nSircoTM, a chilled fruit juice, is the first heart health product to contain the\npatented FruitflowTM technology. FruitflowTM is a natural bioactive extract from\ntomato that works by reducing blood platelet aggregation within hours of\nconsumption. Platelet aggregation plays a significant role in the formation of a\nthrombus (internal blood clot) which can cause a heart attack or stroke.\n\nSircoTM is currently available in the UK in the chilled juice category in over\n550 Tesco and Waitrose stores. The product is targeted at adults who are keen to\nmaintain cardiovascular health.\n\nCommenting on the news of the acceptance by the journal, Dr Stephen Franklin,\nCEO of Provexis, said:\n\n'We are delighted that the science behind FruitflowTM has been accepted for\npublication by the highest-ranked peer-reviewed scientific journal in the field.\nWe have remained resolute in our belief that the FruitflowTM technology is\nworld-class and that this would be recognised by the most stringent scientific\nreview process in the field of clinical nutrition.'\n\n'The acceptance of two separate scientific papers, published in this\ninternationally accredited journal is a significant milestone for the Company\nand an essential precursor to initiating a number of key commercial activities'.\n\n\nFor further information please contact:\n\nProvexis plc\nDr Stephen Franklin 020 8392 6631\n\nBell Pottinger Corporate & Financial\nEmma Kent 020 7861 3232\n\n\n\n\n\n\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length":2317,"tagName":"div"}]